



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,526
Filing Date	November 23, 2003
First Named Inventor	TAM, Cherk Shing
Art Unit	
Examiner Name	
Attorney Docket Number	32404-2054

Sheet 1 of 8

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
DR		US- 4,320,118 A	3/1982	White et al.	
		US- 4,877,864 A	10/1989	Wang et al.	
		US- 4,897,348 A	1/1990	Johnston et al.	
		US- 5,011,691 A	4/1991	Oppermann et al.	
		US- 5,024,841 A	6/1991	Chu et al.	
		US- 5,264,214 A	11/1993	Rhee et al.	
		US- 5,304,542 A	4/1994	Tatakis	
		US- 5,354,557 A	10/1994	Oppermann et al.	
		US- 5,461,034 A	10/1995	Rodan et al.	
		US- 5,470,831 A	11/1995	Whitman et al.	
		US- 5,470,911 A	11/1995	Rhee et al.	
		US- 5,504,190 A	4/1996	Houghton et al.	
		US- 5,578,569 A	11/1996	Tam	
		US- 5,643,549 A	7/1997	Rhodes	
		US- 5,661,127 A	8/1997	Bhatnagar et al.	
		US- 5,776,892 A	7/1998	Counts et al.	
		US- 5,786,327 A	7/1998	Tam	
		US- 5,792,664 A	8/1998	Chait et al.	
		US- 5,880,094 A	3/1999	Tam	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
DR		EP 0451867	10/1991			
		EP 0499242	8/1992			
		EP 0504938	9/1992			
		GB 2231872	7/1992			
		WO 90/00060	1/1990			
		WO 9006321	6/1990			

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/718,526

Filing Date November 23, 2003

First Named Inventor TAM, Cherk Shing

Art Unit

Examiner Name

Attorney Docket Number 32404-2054

Sheet 2 of 8

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
DR ↓		US- 6,117,839 A	9/2000		
		US- 6,274,702 B1	8/2001		
		US- 6,352,973 B1	3/2002		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
DR ↓		WO 91/11515	8/1991			
		WO 92/14481	9/1992			
		WO 94/05309	3/1994			
		WO 94/20615	9/1994			
		WO 95/28172	10/1995			
		WO 97/12036	4/1997			

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,526
Filing Date	November 23, 2003
First Named Inventor	TAM, Cherk Shing
Art Unit	
Examiner Name	
Attorney Docket Number	32404-2054

Sheet 3 of 8

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		DART ET AL. Transforming growth factors from a human tumor cell: characterization of... weight transforming growth factor alpha. Biochemistry, (Oct. 8, 1985) 24 (21) 5925-31.	
		BOWIE ET AL. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science. (Mar. 16, 1990) 247 (4948) 1306-10.	
		NGO ET AL., The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.	
		EHLERT ET AL. J. Biol Chem. Mar. 17, 1995;270(11):6338-44, Oct. 1985.	
		ALFRED WALZ AND MARCO BAGGIOLINI: A Novel Cleavage Product of B-Throm... Human Neutrophils, vol. 159, No. 3, 1989; Mar 31, 1989; pp. 969-975 Theodor-Kocher-Institut, Universi	
		Selye, "On the Stimulation of New Bone-Formation ..." Endocrinology 16: 547-558 (1933).	
		AITKEN ET AL. "Primary Hyperparathyroidism with Osteosclerosis ..." Am. J. Med. 37:813-820 (Nov. 1964).	
		Kalu et al., "Parathyroid Hormone and Experimental ..." Lancet 1363-1366 (Jun. 1970).	
		KLEIN ET AL., "Prostaglandins: Simulation of Bone Resorption ..." Endocrinology 86: 1436-14 1440 (Jun. 1970).	
		CONNOR ET AL., "Generalized Osteosclerosis in Primary ..." Trans Am. Clin. Climato. ASSoc. 85: 185-201 (1973).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,526
Filing Date	November 23, 2003
First Named Inventor	TAM, Cherk Shing
Art Unit	
Examiner Name	
Attorney Docket Number	32404-2054

Sheet 4

of

8

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		GENANT, "Osteosclerosis in Primary Hyperparathyroidism" Am. J. Med. 59: 104-113 (Jul. 1975).	
		RUDINGER ET AL. Peptide Hormones. Parsons, eds., University Park Press, Baltimore, pp. 1-7, 1976.	
		TAM ET AL., "Bone Apposition Rate as an Index of ..." Metabolism 27(2): 143-150 (Feb. 1978).	
		BEGG ET AL., "Complete Covalent Structure of Human.beta-Thromboglobulin", Structure of .beta-Thromboglobulin, vol. 17, No. 9, 1978, pp. 1739-1744.	
		SCHULZ ET AL., Principles of Protein Structure, Springer-Verlag, New York, pp. 14-16, 1979.	
		MARKS ET AL., "The Hematogenous Origin of Osteoclasts: Experimental ..." Am. J. Anat 161:1-10 (1981).	
		CHEN, "Glucocorticoid Regulation of 1.25(OH)2-Vitamin D3 ..." J. Bio. Chem. 257(22):13564-13569 (Nov. 1982).	
		PARFITT, "The Coupling of Bone Formation to Bone ..." Metab. Bone Dis & Rel. Res. 4:1-6 (1982).	
		TAM ET AL., "Parathyroid Hormone Stimulates the Bone ..." Endocrinology 110(2):506-512 (1982).	
↓		C.W.CASTOR ET AL., "Structural and Biological Characteristics of Tissue...Platelet-3 derived Growth Factor", Proc. Natl. Acad. Sci. USA, vol. 80, Fed. 1983, pp. 765-769.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,526
Filing Date	November 23, 2003
First Named Inventor	TAM, Cherk Shing
Art Unit	
Examiner Name	
Attorney Docket Number	32404-2054

Sheet 5 of 8

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		CHYUN, "Stimulation of Bone Formation by Prostaglandin E2" Prostaglandins J. 27(1):97-103 (Jan. 1984).	
		CANALIS, "Effect of Growth Factors on Bone Cell ..." Clin. Orthop. & Rel. Res. 246-263 (1985).	
		<del>OWEN, "Lineage of Osteogenic Cells and Their ..." Bone &amp; Mineral Res. 3 (1):1-25(1985).</del>	
		SUNDELIN ET AL., "The Primary Structure of Rabbit and Rat Prealbumin ..." J. Biol. Chem. 260(10):6481-6487 (May 1985).	
		GEORGE ET AL., Macromolecular Sequencing and Synthesis: Selected Methods and Applications, Schlesinger, ed., Alan R. Liss Inc., New York, pp. 127-149, 1988."	
		CASTOR ET AL., "Connective Tissue Activation-Biologically...From Human Platelets", Biochemical and Biophysical Research Communications, vol. 163, No. 2, 1989, pp. 1071-1078.	
		NODA ET AL. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology, (Jun. 1989) 124(g) 2991-4.	
		TAM, "The Pathogenesis of Metabolic Bone Disease ..." CRC Press, Boca Raton 2: 19-31 (1989).	
		<del></del>	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

<b>Application Number</b>	10/718,526
<b>Filing Date</b>	November 23, 2003
<b>First Named Inventor</b>	TAM, Cherk Shing
<b>Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	32404-2054

Sheet	6	of	8
-------	---	----	---

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		WALZ ET AL., "Generation of the Neutrophil-Activating...Issue-3 Activating Peptide III Through Monocyte Proteases", Journal of Med., vol. 171, Feb. 1990, pp. 449-454.	
		WOZNEY ET AL., J. Cell. Sci. Suppl. 13:149-156 (1990).	
		CASTOR ET AL., "Connective Tissue Activation", Arthritis & Rheumatism, vol. 35, No. 7, Jul. 1992, pp. 783-793.	
		Roodman, "Perspectives: Interleukin-6: an Osteotropic Factor?" J. Bone & Mineral Res. 7(5):475-478 (1992).	
		VAUGHAN ET AL., Identification and Characterization of the Insertion Element IS1070 from <i>Leuconostoc lactis</i> NZ6009, Elsevier Science B.V. pp. 95-100 (1995).	
		NAVAB ET AL., "Rat Plasma Prealbumin" J. Biol. Chem. 252:5100-5106 (Jul. 1997).	
		VAUGHAN ET AL., U17353, <i>Leuconostoc lactis</i> insertium sequence IS1070: Is1070 putative transposase (tnp) gene, complete eds. Sep. 13, 1995.	
		STEDMAN'S MEDICAL DICTIONARY, 27TH edition Medical Economics Company, Inc. 2000.	
		ABSTRACT-WO 92/10515, PHARMA Bissendorf peptide GMBH, Derivatives of the Human Parathormone Fragment (1-37) in the Amide or Ethylamide Form as Active Substance, Jun. 25, 1992.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/718,526
		Filing Date	November 24, 2003
		First Named Inventor	TAM, Cherk Shing
		Art Unit	
		Examiner Name	
Sheet 7	of 8	Attorney Docket Number	32404-2054

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		ABSTRACT-WO 92/15615, Chugai Seiyaku Kabushiki Kaisha, Serum Calcium Depressing Factor, Stp. 17, 1992.	
		COCCIA ET AL. "Successful Bone-Marrow Transplantation ..." New England Journal of Medicine 302(13) 701-708 (1980).	
		CANALIS, "Interleukin-1 has Independ Effects on Deoxribonucleic ..." Endocrinology 118(1):74-81 (1986).	
		CENTRELLA ET AL., "Transforming and Non-Transforming Growth Factors are ..." Proc. Natl. Acad. Sci USA 82:7335-7339 (Nov. 1985).	
		CANALIS, "Effect of Insulin-like Growth Factor I on DNA ..." J. Clin. Invest. 66:709-719 (Oct. 1980).	
		TASHJIAN ET AL. "a and B Human Transforming Growth Factors ..." Proc. Natl. Acad. Sci. USA 82:4535-4538 (Jul., 1985).	
		MAJUMDAR ET AL. "Characterization of the Human B-thromboglobulin ..." J. Bio. Chem 266(9):5785-5787 (Mar. 1991).	
		<del>INTERNATIONAL SEARCH REPORT issued by European Patent Office on international patent application No. PCT/CA96/00653, published Jun. 5, 1997.</del>	
↓		INTERNATIONAL SEARCH REPORT issued by European Patent Office on international patent application No. PCT/CA00/00031, published Jul. 20, 2000.	

Examiner Signature	/David Romeo/ (12/19/2006)	Date Considered	
--------------------	----------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.